Next Article in Journal
Genome Subtraction and Comparison for the Identification of Novel Drug Targets against Mycobacterium avium subsp. hominissuis
Previous Article in Journal
Brucella abortus Proliferates in Decidualized and Non-Decidualized Human Endometrial Cells Inducing a Proinflammatory Response
Open AccessReview

Current Status and Trends in Prophylaxis and Management of Anthrax Disease

Emergent BioSolutions Inc., 300 Professional Drive, Gaithersburg, MD 20879, USA
*
Author to whom correspondence should be addressed.
Pathogens 2020, 9(5), 370; https://doi.org/10.3390/pathogens9050370
Received: 18 February 2020 / Revised: 29 April 2020 / Accepted: 7 May 2020 / Published: 12 May 2020
(This article belongs to the Section Vaccines and Therapeutic Developments)
Bacillus anthracis has been identified as a potential military and bioterror agent as it is relatively simple to produce, with spores that are highly resilient to degradation in the environment and easily dispersed. These characteristics are important in describing how anthrax could be used as a weapon, but they are also important in understanding and determining appropriate prevention and treatment of anthrax disease. Today, anthrax disease is primarily enzootic and found mostly in the developing world, where it is still associated with considerable mortality and morbidity in humans and livestock. This review article describes the spectrum of disease caused by anthrax and the various prevention and treatment options. Specifically we discuss the following; (1) clinical manifestations of anthrax disease (cutaneous, gastrointestinal, inhalational and intravenous-associated); (2) immunology of the disease; (3) an overview of animal models used in research; (4) the current World Health Organization and U.S. Government guidelines for investigation, management, and prophylaxis; (5) unique regulatory approaches to licensure and approval of anthrax medical countermeasures; (6) the history of vaccination and pre-exposure prophylaxis; (7) post-exposure prophylaxis and disease management; (8) treatment of symptomatic disease through the use of antibiotics and hyperimmune or monoclonal antibody-based antitoxin therapies; and (9) the current landscape of next-generation product candidates under development. View Full-Text
Keywords: Animal Rule; anthrax; anthrax therapeutic; anthrax vaccine; antibiotics; Bacillus anthracis; post-exposure prophylaxis; prophylaxis Animal Rule; anthrax; anthrax therapeutic; anthrax vaccine; antibiotics; Bacillus anthracis; post-exposure prophylaxis; prophylaxis
Show Figures

Figure 1

MDPI and ACS Style

Savransky, V.; Ionin, B.; Reece, J. Current Status and Trends in Prophylaxis and Management of Anthrax Disease. Pathogens 2020, 9, 370.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop